CRISPR Therapeutics drew strong retail interest after Phase 1 data showed its experimental gene-editing therapy, CTX310, reduced triglycerides and LDL cholesterol by up to 70% with a solid safety profile. The company plans to advance the therapy into Phase 1b trials. Traders on Stocktwits called it a major breakthrough, with some targeting $70-$100 per share.